• Samir V Patel, Rajesh Sonani, Vikas Singh, Palak Patel, and Apurva Badheka.
• a Department of Medicine , Sparks Health Systems , Fort Smith , AR , USA.
• Expert Rev Pharmacoecon Outcomes Res. 2017 Dec 1; 17 (6): 579-585.

IntroductionPatients with bicuspid aortic valve (BAV) have traditionally been excluded from large randomized clinical trials involving transcatheter aortic valve replacements (TAVR). Technical enhancements, availability of new generation devices and improved outcomes have led to a marked increase in TAVR volume across the world including off label use in patients with BAV stenosis. Areas covered: In this manuscript, we have reviewed the currently available data regarding safety, efficacy, and outcomes of TAVR in patients with BAV stenosis. 11 large observational studies with near 1300 patients with BAV stenosis were included to summarizes outcomes of TAVR. Expert Commentary: The present review suggested that TAVR may be a safe and feasible treatment modality in BAV stenosis patients. New generation devices were associated with high device success rate whereas higher adverse procedural events were observed in early generation devices. There are no differences in post procedural outcomes with new generation TAVR devices for BAV when compared to tricuspid aortic anatomy. Larger studies are needed to evaluate the long-term outcome and durability of TAVR in patients with BAV.

20 keywords...

hide…